PHVS Key Statistics, Chart & Performance
The current stock price of PHVS is 25.04 USD. In the past month the price decreased by -1.22%. In the past year, price increased by 40.67%.
PHVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.39 | 1.05T | ||
| JNJ | JOHNSON & JOHNSON | 19.99 | 499.91B | ||
| MRK | MERCK & CO. INC. | 12.33 | 269.55B | ||
| PFE | PFIZER INC | 7.9 | 143.73B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.65 | 115.47B | ||
| ZTS | ZOETIS INC | 19.82 | 55.38B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 10.07 | 23.89B | ||
| VTRS | VIATRIS INC | 5.35 | 14.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.79 | 11.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.60B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.73B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.06B |
Related stock screener links
About PHVS
Company Profile
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 108 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Company Info
PHARVARIS NV
Emmy Noetherweg 2
Leiden ZUID-HOLLAND NL
CEO: Berndt Modig
Employees: 114
Phone: 31712036410
PHARVARIS NV / PHVS FAQ
Can you describe the business of PHARVARIS NV?
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 108 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
What is the current price of PHVS stock?
The current stock price of PHVS is 25.04 USD. The price increased by 4.12% in the last trading session.
What is the dividend status of PHARVARIS NV?
PHVS does not pay a dividend.
How is the ChartMill rating for PHARVARIS NV?
PHVS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about PHARVARIS NV (PHVS) stock?
18 analysts have analysed PHVS and the average price target is 46.84 USD. This implies a price increase of 87.04% is expected in the next year compared to the current price of 25.04.
How many employees does PHARVARIS NV have?
PHARVARIS NV (PHVS) currently has 114 employees.
PHVS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PHVS. When comparing the yearly performance of all stocks, PHVS is one of the better performing stocks in the market, outperforming 85.97% of all stocks.
PHVS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHVS. PHVS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PHVS Financial Highlights
Over the last trailing twelve months PHVS reported a non-GAAP Earnings per Share(EPS) of -3.43. The EPS decreased by -12.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.31% | ||
| ROE | -52.43% | ||
| Debt/Equity | 0 |
PHVS Forecast & Estimates
18 analysts have analysed PHVS and the average price target is 46.84 USD. This implies a price increase of 87.04% is expected in the next year compared to the current price of 25.04.